Dyer Timothy Mark sold (to issuer) 16,413,787 shares of ADXN
Dyer Timothy Mark (CHIEF EXECUTIVE OFFICER) sold (to issuer) 16,413,787 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
How this was made
The 30-second read
Why it matters
The insider sell is a fresh, material fact that could influence short‑term trading sentiment.
Market read
Primary disclosure of a large insider sale; may prompt short sellers and affect ADXN price.
What to watch
No price disclosed; the sale may have been executed at a favorable price or part of a pre‑arranged plan.
Background
Form 4 filing discloses insider transactions; this is the first public report of the CEO's sale.
Ticker impact
CEO Timothy Dyer sold 16,413,787 shares on 2026-09-02, reducing his stake to 435,192 shares.
downward pressure on ADXN share price
A sale of over 16M shares by the chief executive is material; investors often view such disposals as a negative signal.
Market effects
Minimal impact on the broader biotech sector; insider sales are company‑specific.
Limited to investors tracking ADXN; no regional ripple effect.
Low global relevance.
Counterpoint
The sale could be a routine liquidity move unrelated to fundamentals.
Key entities
- CompanyAddex Therapeutics Ltd.
Biopharmaceutical company listed on Nasdaq under ADXN.
- ExecutiveTimothy Dyer
Chief Executive Officer of Addex Therapeutics.